Posted by Michael Wonder on 20 Dec 2017
Agenda for the March 2018 PBAC meeting
20 December 2017 - The agenda for the March 2018 PBAC meeting is now available.
The PBAC is scheduled to consider 68 submissions. This is comparable to the number of submissions in the agenda for the November 2017 meeting (66).
The 68 submissions are comprised of 59 submissions for a PBS medicine/vaccine/gene therapy, 4 for a PBS medicinal preparation and 5 for a NIP vaccine.
45 (66%) of the 68 submissions are initial submissions.
19 (29%) of the 68 submissions are for a new medicine/new combination product. There is one submission for a new gene therapy (nusinersen sodium) and two submissions for a new biosimilar medicine (etanercept and rituximab).
29 (43%) of the 68 submissions are major submissions. This is the first time since the July 2016 meeting that the number of minor submissions in the agenda is greater than the number of major submissions (July 2016 meeting - 23 major/24 minor)
The technologies in the submissions span many therapeutic areas; the most common ones are:
- Oncology - 13 submissions
- Immunology - 10 submissions
- Haematology - 4 submissions
The companies with the most number of submissions are:
- Pfizer - 6 submissions (2 major)
- MSD - 4 submissions (1 major)
- AstraZeneca - 3 submissions (2 major)
Further details are available upon request.
